Monsanto: An Update for November 2017
Monsanto (MON) released its 4Q17 earnings on October 4, 2017. It reported an adjusted EPS (earnings per share) of $0.2, which beat analysts’ estimate of an EPS of -$0.41. Monsanto stock was virtually unchanged following its earnings. It closed almost 1% lower on November 10 from the company’s stock price before its earnings on October 3.
Monsanto is waiting to complete a merger with Bayer. The companies are waiting for approvals from regulators in certain countries. The deal was expected to close by the end of 2017. However, Bayer filed an extension with European Union regulators, which pushed back the deal’s completion date to early 2018.
Interested in MON? Don't miss the next report.
Receive e-mail alerts for new research on MON
As of November 10, analysts’ ratings for Monsanto were broadly unchanged month-over-month. The consensus mean rating of 17 analysts for Agrium stood at 2.5 with an overall recommendation of a “hold” on the stock
Two analysts have maintained a “strong buy” recommendation on the stock, which was unchanged from the previous month. Four analysts maintained a “buy” recommendation for the next 12-month period. Eleven analysts had a “hold” recommendation during the same period, while none of the analysts have a “sell” or “strong sell” recommendation on the stock.
The current consensus mean target price for Monsanto stood at $125, which was unchanged from $125 in our October update. Comparing Monsanto’s closing price with its November 10 close at $118, it would translate into a 6% upside.
In the next part, we’ll discuss analysts’ ratings for FMC (FMC).